Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 10mg - atomoxetine (atomoxetine hydrochloride) 10mg - miscellaneous central nervous system agents

Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 18mg - atomoxetine (atomoxetine hydrochloride) 18mg - miscellaneous central nervous system agents

Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 25mg - atomoxetine (atomoxetine hydrochloride) 25mg - miscellaneous central nervous system agents

Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 40mg - atomoxetine (atomoxetine hydrochloride) 40mg - miscellaneous central nervous system agents

Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 60mg - atomoxetine (atomoxetine hydrochloride) 60mg - miscellaneous central nervous system agents

Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 80mg - atomoxetine (atomoxetine hydrochloride) 80mg - miscellaneous central nervous system agents

Canada - engelsk - Health Canada

angita pharma inc. - atomoxetine (atomoxetine hydrochloride) - capsule - 100mg - atomoxetine (atomoxetine hydrochloride) 100mg - miscellaneous central nervous system agents

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine capsules are indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of atomoxetine capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)] . a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic tes

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine capsules are indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of atomoxetine capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)] . a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic tes

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 114.3 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.